» Articles » PMID: 35152355

Review of Imaging Techniques for Evaluating Morphological and Functional Responses to the Treatment of Bone Metastases in Prostate and Breast Cancer

Overview
Specialty Oncology
Date 2022 Feb 13
PMID 35152355
Authors
Affiliations
Soon will be listed here.
Abstract

Bone metastases are very common complications associated with certain types of cancers that frequently negatively impact the quality of life and functional status of patients; thus, early detection is necessary for the implementation of immediate therapeutic measures to reduce the risk of skeletal complications and improve survival and quality of life. There is no consensus or universal standard approach for the detection of bone metastases in cancer patients based on imaging. Endorsed by the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) a group of experts met to discuss and provide an up-to-date review of our current understanding of the biological mechanisms through which tumors spread to the bone and describe the imaging methods available to diagnose bone metastasis and monitor their response to oncological treatment, focusing on patients with breast and prostate cancer. According to current available data, the use of next-generation imaging techniques, including whole-body diffusion-weighted MRI, PET/CT, and PET/MRI with novel radiopharmaceuticals, is recommended instead of the classical combination of CT and bone scan in detection, staging and response assessment of bone metastases from prostate and breast cancer.Clinical trial registration: Not applicable.

Citing Articles

AI-Assisted Detection and Localization of Spinal Metastatic Lesions.

Edelmers E, Nikulins A, Sprudza K, Stapulone P, Puce N, Skrebele E Diagnostics (Basel). 2024; 14(21).

PMID: 39518425 PMC: 11545154. DOI: 10.3390/diagnostics14212458.


Bone scintigraphy based on deep learning model and modified growth optimizer.

Magdy O, Elaziz M, Dahou A, Ewees A, Elgarayhi A, Sallah M Sci Rep. 2024; 14(1):25627.

PMID: 39465262 PMC: 11514163. DOI: 10.1038/s41598-024-73991-8.


18F-fluorodeoxyglucose positron emission tomography-computed tomography in the localization of the lesions in the osteogenic region of breast cancer bone metastases after therapy.

Lin R, Lv H, Yu J, Song C, Tian A Quant Imaging Med Surg. 2024; 14(7):4950-4964.

PMID: 39022246 PMC: 11250318. DOI: 10.21037/qims-23-1738.


The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.

Raoufinia R, Afrasiabi P, Dehghanpour A, Memarpour S, Sayyed Hosseinian S, Saburi E Microrna. 2024; 13(3):175-201.

PMID: 39005129 DOI: 10.2174/0122115366298799240625115843.


Complete fatty replacement of lytic bone metastases following treatment. A case report, assessing response to treatment of bone metastases on CT imaging.

Omotade A, Malhotra A, Holloway B Radiol Case Rep. 2023; 19(1):455-458.

PMID: 38046922 PMC: 10692371. DOI: 10.1016/j.radcr.2023.09.044.


References
1.
Coleman R . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2):6243s-6249s. DOI: 10.1158/1078-0432.CCR-06-0931. View

2.
Amelot A, Terrier L, Le Nail L, Cristini J, Cook A, Buffenoir K . Spine metastasis in patients with prostate cancer: Survival prognosis assessment. Prostate. 2020; 81(2):91-101. DOI: 10.1002/pros.24084. View

3.
Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

4.
Reddington J, Mendez G, Ching A, Dai Kubicky C, Klimo Jr P, Ragel B . Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic. Surg Neurol Int. 2016; 7(Suppl 13):S361-5. PMC: 4879848. DOI: 10.4103/2152-7806.182549. View

5.
Kawai A, Martinez D, Saltus C, Vassilev Z, Soriano-Gabarro M, Kaye J . Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US. Prostate Cancer. 2019; 2019:5971615. PMC: 6652049. DOI: 10.1155/2019/5971615. View